Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Jul
09
Today In Oncology
GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
Intraoperative Margin Assessment With Specimen PET/CT Imaging in Early Breast Cancer
No Survival Benefit From Chemoradiotherapy After D2 Gastrectomy in Gastric Cancer
All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML
Investigators Identify Resistance Mechanism to Tagraxofusp Among Patients With BPDCN
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo